PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
4.46M / 3.59M (Avg.)
-1.65 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.77%
Positive 5Y CAGR while CRN.AX is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
2.46%
3Y revenue/share CAGR under 50% of CRN.AX's 70.35%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
359.87%
OCF/share CAGR of 359.87% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-33.91%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
138.76%
3Y OCF/share CAGR above 1.5x CRN.AX's 18.58%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
29.54%
10Y net income/share CAGR of 29.54% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
957.27%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
298.41%
3Y net income/share CAGR above 1.5x CRN.AX's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-89.86%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
209.87%
Positive 5Y equity/share CAGR while CRN.AX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1153.54%
3Y equity/share CAGR above 1.5x CRN.AX's 44.12%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6126955.88%
3Y dividend/share CAGR of 6126955.88% while CRN.AX is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.